Inhibitors targeting the SUMOylation pathway: A patent review 2012‑2015 (Review)

Zhou,Yanjun; Ji,Chunmei; Cao,Mengda; Guo,Miao; Huang,Wen; Ni,Weiwei; Meng,Ling; Yang,Haiwei; Wei,Ji‑Fu

doi:10.3892/ijmm.2017.3231

Inhibitors targeting the SUMOylation pathway: A patent review 2012‑2015 (Review)

Authors:
- Yanjun Zhou
- Chunmei Ji
- Mengda Cao
- Miao Guo
- Wen Huang
- Weiwei Ni
- Ling Meng
- Haiwei Yang
- Ji‑Fu Wei
View Affiliations

Affiliations: Research Division of Clinical Pharmacology, Jiangsu Province People's Hospital, Nanjing, Jiangsu 210029, P.R. China, Department of Urology, Jiangsu Province People's Hospital, Nanjing, Jiangsu 210029, P.R. China
Published online on: November 1, 2017 https://doi.org/10.3892/ijmm.2017.3231
Pages: 3-12

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Small ubiquitin‑related modifier (SUMO) proteins bind to the lysine residue of target proteins to produce functionally mature proteins. The abnormal SUMOylation of certain target proteins is associated with diseases including cancer, heart disease, diabetes, arthritis, degenerative diseases and brain ischemia/stroke. Thus, there has been growing appreciation for the potential importance of the SUMO conjugation pathway as a target for treating these diseases. This review introduces the important steps in the reversible SUMOylation pathway. The SUMO inhibitors disclosed in the patents between 2012 and 2015 are divided into different categories according to their mechanisms of action. Certain compounds disclosed in this review have also been reported in other articles for their inhibition of the SUMOylation pathway following screening in cell lines. Although there are few studies using animal models or clinical trials that have used these compounds, the application of bortezomin, a ubiquitylation inhibitor, for treating cancer indicates that SUMO inhibitors may be clinically successful.

View Figures

View References

1	Herrmann J, Lerman LO and Lerman A: Ubiquitin and ubiquitin-like proteins in protein regulation. Circ Res. 100:1276–1291. 2007. View Article : Google Scholar : PubMed/NCBI
2	Flotho A and Melchior F: Sumoylation: A regulatory protein modification in health and disease. Annu Rev Biochem. 82:357–385. 2013. View Article : Google Scholar : PubMed/NCBI
3	Bohren KM, Nadkarni V, Song JH, Gabbay KH and Owerbach D: A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J Biol Chem. 279:27233–27238. 2004. View Article : Google Scholar : PubMed/NCBI
4	Geiss-Friedlander R and Melchior F: Concepts in sumoylation: A decade on. Nat Rev Mol Cell Biol. 8:947–956. 2007. View Article : Google Scholar : PubMed/NCBI
5	Tatham MH, Jaffray E, Vaughan OA, Desterro JM, botting CH, Naismith JH and Hay RT: Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem. 276:35368–35374. 2001. View Article : Google Scholar : PubMed/NCBI
6	Yang W and Paschen W: SUMO proteomics to decipher the SUMO-modified proteome regulated by various diseases. Proteomics. 15:1181–1191. 2015. View Article : Google Scholar :
7	Hannich JT, Lewis A, Kroetz MB, Li SJ, Heide H, Emili A and Hochstrasser M: Defining the SUMO-modified proteome by multiple approaches in Saccharomyces cerevisiae. J Biol Chem. 280:4102–4110. 2005. View Article : Google Scholar
8	Hecker CM, Rabiller M, Haglund K, Bayer P and Dikic I: Specification of SUMO1- and SUMO2-interacting motifs. J Biol Chem. 281:16117–16127. 2006. View Article : Google Scholar : PubMed/NCBI
9	Song J, Durrin LK, Wilkinson TA, Krontiris TG and Chen Y: Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc Natl Acad Sci USA. 101:14373–14378. 2004. View Article : Google Scholar : PubMed/NCBI
10	Kumar A and Zhang KY: Advances in the development of SUMO specific protease (SENP) inhibitors. Comput Struct Biotechnol J. 13:204–211. 2015. View Article : Google Scholar : PubMed/NCBI
11	Hickey CM, Wilson NR and Hochstrasser M: Function and regulation of SUMO proteases. Nat Rev Mol Cell Biol. 13:755–766. 2012. View Article : Google Scholar : PubMed/NCBI
12	Bettermann K, Benesch M, Weis S and Haybaeck J: SUMOylation in carcinogenesis. Cancer Lett. 316:113–125. 2012. View Article : Google Scholar
13	Olsen SK, Capili AD, Lu X, Tan DS and Lima CD: Active site remodelling accompanies thioester bond formation in the SUMO E1. Nature. 463:906–912. 2010. View Article : Google Scholar : PubMed/NCBI
14	Kumar A, Ito A, Hirohama M, Yoshida M and Zhang KY: Identification of sumoylation inhibitors targeting a predicted pocket in Ubc9. J Chem Inf Model. 54:2784–2793. 2014. View Article : Google Scholar : PubMed/NCBI
15	Kumar A, Ito A, Hirohama M, Yoshida M and Zhang KY: Identification of sumoylation activating enzyme 1 inhibitors by structure-based virtual screening. J Chem Inf Model. 53:809–820. 2013. View Article : Google Scholar : PubMed/NCBI
16	Mattoscio D and Chiocca S: SUMO pathway components as possible cancer biomarkers. Future Oncol. 11:1599–1610. 2015. View Article : Google Scholar : PubMed/NCBI
17	Schulz S, Chachami G, Kozaczkiewicz L, Winter U, Stankovic-Valentin N, Haas P, Hofmann K, Urlaub H, Ovaa H, Wittbrodt J, et al: Ubiquitin-specific protease-like 1 (USPL1) is a SUMO isopeptidase with essential, non-catalytic functions. EMbO Rep. 13:930–938. 2012. View Article : Google Scholar : PubMed/NCBI
18	Shin EJ, Shin HM, Nam E, Kim WS, Kim JH, Oh BH and Yun Y: DeSUMOylating isopeptidase: A second class of SUMO protease. EMBO Rep. 13:339–346. 2012. View Article : Google Scholar : PubMed/NCBI
19	Shirong L and Wei H: Sumoylation - a muitffunctional post-translational protein modification. J Med Mol Biol. 3:212–215. 2006.
20	Liu X, Xu Y, Pang Z, Guo F, Qin Q, Yin T, Sang Y, Feng C, Li X, Jiang L, et al: Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer. J Hematol Oncol. 8:672015. View Article : Google Scholar : PubMed/NCBI
21	Chen SF, Gong C, Luo M, Yao HR, Zeng YJ and Su FX: Ubc9 expression predicts chemoresistance in breast cancer. Chin J Cancer. 30:638–644. 2011. View Article : Google Scholar : PubMed/NCBI
22	Rabellino A, Carter B, Konstantinidou G, Wu SY, Rimessi A, byers LA, Heymach JV, Girard L, Chiang CM, Teruya-Feldstein J, et al: The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer Res. 72:2275–2284. 2012. View Article : Google Scholar : PubMed/NCBI
23	Li T, Huang S, Dong M, Gui Y and Wu D: Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy. Urol Oncol. 31:1539–1545. 2013. View Article : Google Scholar
24	Bossis G, Sarry JE, Kifagi C, Ristic M, Saland E, Vergez F, Salem T, Boutzen H, Baik H, Brockly F, et al: The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs. Cell Rep. 7:1815–1823. 2014. View Article : Google Scholar : PubMed/NCBI
25	Dassouki Z, Sahin U, El Hajj H, Jollivet F, Kfoury Y, Lallemand-Breitenbach V, Hermine O, de Thé H and Bazarbachi A: ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation. Blood. 125:474–482. 2015. View Article : Google Scholar
26	Chen Y, Horne D, Li YJ, Ma LY, Perkins-Harki AL and Su Y: Multi-valent poly-ubl chain inhibitors and methods of use. US Patent 0302815. Filed February 21, 2012; issued August 5, 2014.
27	Zhao B, Villhauer EB, Bhuripanyo K, Kiyokawa H, Schindelin H and Yin J: SUMO-mimicking peptides inhibiting protein SUMOylation. Chembiochem. 15:2662–2666. 2014. View Article : Google Scholar : PubMed/NCBI
28	Butterworth KT, Coulter JA, Jain S, Forker J, McMahon SJ, Schettino G, Prise KM, Currell FJ and Hirst DG: Evaluation of cytotoxicity and radiation enhancement using 1.9 nm gold particles: Potential application for cancer therapy. Nanotechnology. 21:2951012010. View Article : Google Scholar : PubMed/NCBI
29	Li YJ, Perkins AL, Su Y, Ma Y, Colson L, Horne DA and Chen Y: Gold nanoparticles as a platform for creating a multivalent poly-SUMO chain inhibitor that also augments ionizing radiation. Proc Natl Acad Sci USA. 109:4092–4097. 2012. View Article : Google Scholar : PubMed/NCBI
30	Chithrani DB, Jelveh S, Jalali F, van Prooijen M, Allen C, Bristow RG, Hill RP and Jaffray DA: Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat Res. 173:719–728. 2010. View Article : Google Scholar : PubMed/NCBI
31	Langston SP, Olhava EJ and Vyskocil S: Inhibitors of E1 activating enzymes. EP Patent 2402334 A1. Filed February 2, 2006; issued Junuary 26, 2012.
32	Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, et al: An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 458:732–736. 2009. View Article : Google Scholar : PubMed/NCBI
33	Diffey MO, England Db, Hu ZG, Ito M, Langston SP, Mcintyre C, Mizutani H and Xu H: Heteroaryl compounds useful as inhibitors of SUMO activating enzyme. WO Patent 2015002994 A2. Filed July 1, 2014; issued January 8, 2015.
34	Driscoll JJ, Pelluru D, Lefkimmiatis K, Fulciniti M, Prabhala RH, Greipp PR, Barlogie B, Tai YT, Anderson KC, Shaughnessy JD Jr, et al: The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 115:2827–2834. 2010. View Article : Google Scholar :
35	Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, et al: A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 335:348–353. 2012. View Article : Google Scholar
36	Chen Y, Li YJ, Divlianska D, Bobkova E and Roth G: Singleton inhibitors of SUMOylation enzymes and methods for their use. US Patent 20130317101 A1. Filed May 9, 2013; issued November 28, 2013.
37	Chen Y and Li YJ: Singleton inhibitors of SUMOylation enzymes and methods for their use. WO Patent 064898 A1. Filed May 9, 2013; issued January 19, 2016.
38	Maas M, Nelemans PJ, Valentini V, Crane CH, Capirci C, Rödel C, Nash GM, Kuo LJ, Glynne-Jones R, García-Aguilar J, et al: Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients. Int J Cancer. 137:212–220. 2015. View Article : Google Scholar
39	García-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee SH, Madoff RD and Rothenberger DA: A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum. 46:298–304. 2003. View Article : Google Scholar : PubMed/NCBI
40	Chen Y and Li YJ: Bicyclic and tricyclic inhibitors of SUMOylation enzymes and methods for their use. WO Patent 064897 A2. Filed November 9, 2011; issued May 18, 2012.
41	Chen Y, Li YJ, Divlianska D, Bobkova E, Roth G, Jun PU and Khan P: Bicyclic and tricyclic inhibitors of SUMOylation enzymes and methods for their use. US Patent 20130245032 A1. Filed May 9, 2013; issued September 19, 2013.
42	Chen Y, Li YJ, Divlianska D, bobkova E, Roth G, Jun PU and Khan P: Inhibitors of small ubiquitin-like modifier enzymes with substituted pyrrolo(2,3-B)quinoxalines. US Patent 9045483 B2. Filed May 9, 2013; issued June 2, 2015.
43	Lalonde JP, Lim R, Scaife R, Gallagher S and Klinken SP: HLS-5 a control SUMOylation agent. EP Patent 2545935 A1. Filed October 6, 2006; issued January 16, 2013.
44	Klinken SP, Lalonde JP, Lim R, Scaife R and Gallagher S: SUMOylation control agent and uses thereof. US Patent 20130330738 A1. Filed Junuary 4, 2013; issued December 12, 2013.
45	Knuutila S, Aalto Y, Autio K, Björkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, et al: DNA copy number losses in human neoplasms. Am J Pathol. 155:683–694. 1999. View Article : Google Scholar : PubMed/NCBI
46	Lalonde JP, Lim R, Ingley E, Tilbrook PA, Thompson MJ, McCulloch R, Beaumont JG, Wicking C, Eyre HJ, Sutherland GR, et al: HLS5, a novel RBCC (ring finger, B box, coiled-coil) family member isolated from a hemopoietic lineage switch, is a candidate tumor suppressor. J Biol Chem. 279:8181–8189. 2004. View Article : Google Scholar
47	Kimura F, Suzu S, Nakamura Y, Nakata Y, Yamada M, Kuwada N, Matsumura T, Yamashita T, Ikeda T, Sato K, et al: Cloning and characterization of a novel RING-B-box-coiled-coil protein with apoptotic function. J Biol Chem. 278:25046–25054. 2003. View Article : Google Scholar : PubMed/NCBI
48	Alshareeda AT, Negm OH, Green AR, Nolan C, Tighe P, Albarakati N, Sultana R, Madhusudan S, Ellis IO and Rakha EA: SUMOylation proteins in breast cancer. Breast Cancer Res Treat. 144:519–530. 2014. View Article : Google Scholar : PubMed/NCBI
49	Coppola D, Parikh V, boulware D and Blanck G: Substantially reduced expression of PIAS1 is associated with colon cancer development. J Cancer Res Clin Oncol. 135:1287–1291. 2009. View Article : Google Scholar : PubMed/NCBI
50	Chen P, Zhao D, Sun Y, Huang L, Zhang S and Yuan Y: Protein inhibitor of activated STAT-1 is downregulated in gastric cancer tissue and involved in cell metastasis. Oncol Rep. 28:2149–2155. 2012. View Article : Google Scholar : PubMed/NCBI
51	Wei J, Costa C, Ding Y, Zou Z, Yu L, Sanchez JJ, Qian X, Chen H, Gimenez-Capitan A, Meng F, et al: mRNA expression of bRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst. 103:1552–1556. 2011. View Article : Google Scholar : PubMed/NCBI
52	Hoefer J, Schäfer G, Klocker H, Erb HH, Mills IG, Hengst L, Puhr M and Culig Z: PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am J Pathol. 180:2097–2107. 2012. View Article : Google Scholar : PubMed/NCBI
53	Chen Y, Li S, Li S, Li YJ, Su Y, Wong S and Zaia J: Inhibitors of deSUMOylation enzymes and methods for their use. WO Patent 2012064887 A1. Filed November 9, 2011; issued May 18, 2012.
54	Chen Y: Methods of identifying SENP1 inhibitors. US Patent 20140302525 A1. Filed April 7, 2014; issued October 9, 2014.
55	Madu IG, Namanja AT, Su Y, Wong S, Li YJ and Chen Y: Identification and characterization of a new chemotype of noncovalent SENP inhibitors. ACS Chem Biol. 8:1435–1441. 2013. View Article : Google Scholar : PubMed/NCBI
56	Chen CH, Namanja AT and Chen Y: Conformational flexibility and changes underlying activation of the SUMO-specific protease SENP1 by remote substrate binding. Nat Commun. 5:49682014. View Article : Google Scholar : PubMed/NCBI
57	Madu IG, Li S, Li B, Li H, Chang T, Li YJ, Vega R, Rossi J, Yee JK, Zaia J, et al: A Novel Class of HIV-1 Antiviral Agents Targeting HIV via a SUMOylation-Dependent Mechanism. Sci Rep. 5:178082015. View Article : Google Scholar : PubMed/NCBI
58	Wang LS, Sun HY, Wu ZZ, Xiao FJ, Wang H and Yang YF: SENP1 protein inhibitors and uses thereof. CN Patent 104436196 A. Filed September 23, 2013; issued March 25, 2015.
59	Zhang J, Cheng JK, Lu SY, Cheng YY, Zhang JM and Huang M: Senp1 small molecule inhibitors and their applications. CN Patent 103961348 B. Filed February 5, 2013; issued August 17, 2016.
60	Chen Y, Wen D, Huang Z, Huang M, Luo Y, Liu B, Lu H, Wu Y, Peng Y and Zhang J: 2-(4-Chlorophenyl)-2-oxoethyl 4-benzamidobenzoate derivatives, a novel class of SENP1 inhibitors: Virtual screening, synthesis and biological evaluation. Bioorg Med Chem Lett. 22:6867–6870. 2012. View Article : Google Scholar : PubMed/NCBI
61	Cheng J, Kang X, Zhang S and Yeh ET: SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell. 131:584–595. 2007. View Article : Google Scholar : PubMed/NCBI
62	Bawa-Khalfe T, Cheng J, Lin SH, Ittmann MM and Yeh ET: SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem. 285:25859–25866. 2010. View Article : Google Scholar : PubMed/NCBI
63	Yamaguchi T, Sharma P, Athanasiou M, Kumar A, Yamada S and Kuehn MR: Mutation of SENP1/SuPr-2 reveals an essential role for desumoylation in mouse development. Mol Cell Biol. 25:5171–5182. 2005. View Article : Google Scholar : PubMed/NCBI
64	Cheng J, Bawa T, Lee P, Gong L and Yeh ET: Role of desumoylation in the development of prostate cancer. Neoplasia. 8:667–676. 2006. View Article : Google Scholar : PubMed/NCBI
65	Zhang J, Cheng JK, Huang M, Chen YY, Huang ZM, Lu SY and Shi T: SENP2 small molecule inhibitor and applications thereof. CN Patent 103877078 A. Filed December 20, 2012; issued June 25, 2014.
66	Dou QP and Zonder JA: Overview of proteasome inhibitor-based anticancer therapies: Perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets. 14:517–536. 2014. View Article : Google Scholar
67	Chen JW, Ink BS and Lewis AP: Cysteine protease polypeptides GB2371801. 2002
68	Ink BS and Lewis AP: Cysteine protease polypeptide GB2372504. 2002
69	Chen JW, Ink BS and Lewis AP: Cysteine protease polypeptide GB2372994. 2002
70	Ink BS: Protease polypeptide GB2382078. 2003
71	Góra J and Latajka R: Involvement of cysteine proteases in cancer. Curr Med Chem. 22:944–957. 2015. View Article : Google Scholar
72	Wu HJ, Liu WD, Hong YD and Guo QP: Identification of a breast cancer suppressor and methods for use CN101923095. 2010
73	German RA and Sangita P: Modulation of cellular protein function by artifical SUMO ligases. US Patent 20120246757 A1. Filed March 22, 2012; issued September 27, 2012.